Angeliq is a prescription hormone therapy tablet that combines two active ingredients, estradiol (a form of estrogen) and drospirenone (a synthetic progestin), in a single daily pill. It’s FDA-approved for postmenopausal women to treat moderate to severe hot flashes and to help prevent osteoporosis. Because it contains both estrogen and a progestin, it’s designed specifically for women who still have a uterus and need the protective effect of progestin on the uterine lining.
What Angeliq Contains and How It Works
Each Angeliq tablet delivers a low dose of estradiol (0.5 mg) paired with drospirenone (0.25 mg). The estradiol replaces the estrogen your body stops producing after menopause, which is the direct cause of hot flashes, night sweats, and vaginal dryness. Estrogen therapy on its own, however, can cause the uterine lining to grow abnormally over time. That’s where drospirenone comes in: it counteracts estrogen’s effect on the uterus by slowing cell growth in the endometrial tissue, reducing the risk of uterine cancer.
What makes drospirenone different from the progestins used in other hormone therapies is its chemical similarity to spironolactone, a medication known for blocking the hormone aldosterone. This gives drospirenone antimineralocorticoid properties, meaning it can counteract the water-retaining effects that estrogen sometimes causes. It also has anti-androgen activity, so it doesn’t promote acne or excess hair growth the way some other progestins can. It carries no cortisol-like effects in either direction.
How Well It Reduces Hot Flashes
In the pivotal clinical trial used for FDA approval, 735 postmenopausal women age 40 and older were enrolled. All participants had at least 7 to 8 moderate to severe hot flashes per day (or 50 to 60 per week) at the start of the study. Women taking Angeliq started with an average of about 10.7 hot flashes daily.
By week 4, women on Angeliq experienced roughly 5.5 fewer daily hot flashes compared to baseline, while those on placebo saw a reduction of about 3.4. That translates to about 2 additional hot flashes eliminated per day beyond the placebo effect. By week 12, the gap widened further: Angeliq users had about 7.7 fewer daily episodes versus 4.5 fewer in the placebo group, a difference of roughly 3 extra hot flashes eliminated each day. Both results were statistically significant.
Effects on Blood Pressure and Weight
One common concern with hormone therapy is water retention and its impact on weight and blood pressure. Because drospirenone works against aldosterone, the hormone that tells your kidneys to hold onto sodium and water, Angeliq may have a neutral or mildly favorable effect on fluid balance compared to other hormone therapies. Research on drospirenone-containing medications in hypertensive women found no significant changes in blood pressure, body measurements, or metabolic markers after six months of use. This is a notable difference from some older progestins that can contribute to bloating and mild blood pressure increases.
How to Take It
Angeliq is taken as one tablet daily, swallowed whole with liquid, with or without food. Taking it at the same time each day helps maintain steady hormone levels. If you miss a dose, take it as soon as you remember. If more than 24 hours have passed, skip the missed tablet entirely and continue with your regular schedule. Missing several tablets in a row may trigger breakthrough bleeding.
Who Should Not Take Angeliq
Angeliq carries the same boxed warning that applies to all estrogen-progestin hormone therapies. Combined hormone therapy has been associated with increased risks of stroke, blood clots in the legs and lungs, and breast cancer. These risks are generally small in absolute terms for women in their 50s who are close to menopause onset, but they increase with age and duration of use. The general recommendation is to use the lowest effective dose for the shortest time needed to manage symptoms.
Because drospirenone can raise potassium levels, Angeliq is not appropriate for women with adrenal insufficiency, kidney impairment, or liver disease. Women already taking medications that increase potassium (certain blood pressure drugs, potassium-sparing diuretics, or potassium supplements) need careful monitoring if prescribed Angeliq. It’s also contraindicated in women with a history of breast cancer, unexplained uterine bleeding, or blood clotting disorders.
How Angeliq Compares to Other HRT Options
Most combined hormone therapy pills pair estradiol with a progestin like medroxyprogesterone acetate or norethindrone acetate. These older progestins get the job done in protecting the uterus but can sometimes cause side effects like bloating, mood changes, or mild androgenic effects such as oily skin. Drospirenone’s anti-androgen and anti-water-retention properties make Angeliq a distinct option within the category, particularly for women who have experienced fluid-related side effects on other formulations.
Angeliq is also positioned as a low-dose option. Its 0.5 mg estradiol content is lower than what many standard-dose hormone therapies provide (typically 1 mg oral estradiol), which may reduce estrogen-related side effects while still offering meaningful relief from vasomotor symptoms.